This study is testing a drug called olverembatinib (HQP1351) for people with chronic phase chronic myeloid leukemia (CP-CML), a type of blood cancer. It compares olverembatinib to another drug, bosutinib, in some patients. You might be able to join if you are 18 or older and have CP-CML. If you're in Part A, you would have already tried at least two other approved treatments. If you're in Part B, you would have a specific genetic change called the T315I mutation. The main goal is to see if olverembatinib leads to a higher major molecular response (MMR) rate, which means a significant reduction in cancer cells, after 24 weeks.

Study design

This is a global, multi-center, open-label (meaning you and your doctor will know which treatment you receive), randomized (meaning you're assigned to a treatment by chance) study. It plans to enroll 285 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints are measured at 24 weeks, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.